A case of anti-laminin γ1 (p200) pemphigoid with psoriasis vulgaris successfully treated with apremilast

[1] Dainichi T(2009)Anti–laminin gamma–1 pemphigoid Proc Natl Acad Sci USA 106 2800-5

[2] Kurono S(2010)From anti–p200 pemphigoid to anti–laminin gamma1 pemphigoid J Dermatol 37 231-8

[3] Ohyama B(2014)Anti–p200 pemphigoid J Am Acad Dermatol 71 185-91

[4] Dainichi T(2017)Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis:efficacy, safety and tolerability results from a phase 2b randomized controlled trial J Dermatol 44 873-84

[5] Koga H(2010)Apremilast, a cAMP phosphodiesterase–4 inhibitor, demonstrates anti–inflammatory activity in vitro and in a model of psoriasis Br J Pharmacol 159 842-55

[6] Tsuji T(2015)Apremilast for Behcet’s syndrome–a phase 2, placebo–controlled study N Engl J Med 372 1510-8

[7] Goletz S(2016)Apremilast use for moderate–tosevere atopic dermatitis in pediatric patients Case Rep Dermatol 8 179-84

[8] Hashimoto T(undefined)undefined undefined undefined undefined-undefined

[9] Zillikens D(undefined)undefined undefined undefined undefined-undefined

[10] Schmidt E(undefined)undefined undefined undefined undefined-undefined

[1] Dainichi T(2009)Anti–laminin gamma–1 pemphigoid Proc Natl Acad Sci USA 106 2800-5

[2] Kurono S(2010)From anti–p200 pemphigoid to anti–laminin gamma1 pemphigoid J Dermatol 37 231-8

[3] Ohyama B(2014)Anti–p200 pemphigoid J Am Acad Dermatol 71 185-91

[4] Dainichi T(2017)Apremilast, an oral phosphodiesterase 4 inhibitor, in the treatment of Japanese patients with moderate to severe plaque psoriasis:efficacy, safety and tolerability results from a phase 2b randomized controlled trial J Dermatol 44 873-84

[5] Koga H(2010)Apremilast, a cAMP phosphodiesterase–4 inhibitor, demonstrates anti–inflammatory activity in vitro and in a model of psoriasis Br J Pharmacol 159 842-55

[6] Tsuji T(2015)Apremilast for Behcet’s syndrome–a phase 2, placebo–controlled study N Engl J Med 372 1510-8

[7] Goletz S(2016)Apremilast use for moderate–tosevere atopic dermatitis in pediatric patients Case Rep Dermatol 8 179-84

[8] Hashimoto T(undefined)undefined undefined undefined undefined-undefined

[9] Zillikens D(undefined)undefined undefined undefined undefined-undefined

[10] Schmidt E(undefined)undefined undefined undefined undefined-undefined